We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.93%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$973M
AUM Growth
-$259M
Cap. Flow
-$139M
Cap. Flow %
-14.32%
Top 10 Hldgs %
31.9%
Holding
97
New
2
Increased
29
Reduced
54
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$13.3M
2
CI icon
Cigna
CI
+$11.7M
3
BIIB icon
Biogen
BIIB
+$9.55M
4
HUM icon
Humana
HUM
+$6.5M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.19M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$15.7M
2
BDX icon
Becton Dickinson
BDX
+$14.9M
3
HCA icon
HCA Healthcare
HCA
+$14.6M
4
BSX icon
Boston Scientific
BSX
+$12.9M
5
COO icon
Cooper Companies
COO
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMDX icon
76
Transmedics
TMDX
$3.03B
$2.37M 0.24%
38,000
-7,270
-16% -$677K
PRVA icon
77
Privia Health
PRVA
$2.82B
$2.37M 0.24%
121,189
+26,000
+27% +$515K
MEDP icon
78
Medpace
MEDP
$16.8B
$2.26M 0.23%
6,800
-700
-9% -$237K
ALKS icon
79
Alkermes
ALKS
$8.25B
$2.24M 0.23%
77,999
-55,001
-41% -$1.58M
BRKR icon
80
Bruker
BRKR
$8.55B
$2.13M 0.22%
36,315
-8,000
-18% -$473K
IDYA icon
81
IDEAYA Biosciences
IDYA
$3.54B
$2.11M 0.22%
82,000
-45,500
-36% -$1.29M
RLAY icon
82
Relay Therapeutics
RLAY
$4.41B
$1.9M 0.19%
460,000
– –
IMCR icon
83
Immunocore
IMCR
$1.75B
$1.72M 0.18%
58,278
– –
PLRX icon
84
Pliant Therapeutics
PLRX
$65.6M
$1.53M 0.16%
116,250
-4,000
-3% -$54.6K
XENE icon
85
Xenon Pharmaceuticals
XENE
$6.2B
$1.37M 0.14%
35,000
– –
AVTR icon
86
Avantor
AVTR
$9.28B
$1.3M 0.13%
61,826
+17,826
+41% +$401K
RGEN icon
87
Repligen
RGEN
$9.28B
$1.3M 0.13%
9,000
-1,000
-10% -$143K
INMB icon
88
INmune Bio
INMB
$56.6M
$833K 0.09%
178,284
– –
AMGN icon
89
Amgen
AMGN
$224B
$782K 0.08%
3,000
– –
IGMS
90
DELISTED
IGM Biosciences
IGMS
$770K 0.08%
126,064
-59,395
-32% -$706K
ACHC icon
91
Acadia Healthcare
ACHC
$2.91B
$545K 0.06%
13,750
-92,000
-87% -$4.15M
TECH icon
92
Bio-Techne
TECH
$11.2B
$216K 0.02%
3,000
-17,000
-85% -$1.25M
BBIO icon
93
BridgeBio Pharma
BBIO
$16.6B
– –
-268,000
Closed -$6.82M
DXCM icon
94
DexCom
DXCM
$33.5B
– –
-87,000
Closed -$5.83M
EPIX
95
DELISTED
ESSA Pharma
EPIX
– –
-804,649
Closed -$4.88M
EVH icon
96
Evolent Health
EVH
$485M
– –
-265,000
Closed -$7.49M
MDGL icon
97
Madrigal Pharmaceuticals
MDGL
$12.2B
– –
-15,300
Closed -$3.25M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Rhenman & Partners Asset Management held 97 positions worth $973M, down 21% from $1.23B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $139M in Q4 2024, closing 5 positions and reducing 54 holdings. Its most notable exit was Evolent Health, an estimated $7.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Zimmer Biomet worth $13.1M.

  • Rhenman & Partners Asset Management's largest Q4 2024 buy was Zimmer Biomet: 124,000 shares worth $13.1M.
  • Rhenman & Partners Asset Management added most to Cigna in Q4 2024, an estimated $11.7M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2024 reduction was Natera, cutting an estimated $15.7M.
  • Rhenman & Partners Asset Management fully exited Evolent Health in Q4 2024, selling an estimated $7.49M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $973M portfolio in Q4 2024.
  • Rhenman & Partners Asset Management opened 2 new positions and closed 5 in Q4 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 21% quarter-over-quarter to $973M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.